Sebastian Gensior’s Post

The healthtech market is projected to reach a valuation of $549.7B by 2028, growing at a CAGR of 25%. So which are some of the most prominent VC funds investing in the field? TMV : The New York-based fund aims to reimagine the future of care, work, and other sectors, having invested in companies like Tali.ai, ProcessLabs and Millie. Novo Holdings: It’s responsible for managing the assets and wealth of the Novo Nordisk Foundation, one of the world’s largest enterprise foundations. InHealth Ventures: The fund helps build companies that can address urgent, pervasive and substantive healthcare challenges at scale. Which other fund would you add to the list? #vdkcapital #healthtech

I firmly believe in the power of communities and platforms that unite people. Why? Because finding the right partners in healthcare innovation can feel like searching for a needle in a haystack. That's why VentureBlick has just launched its Discovery platform for the healthcare innovation community! 👨⚕️ 👩⚕️ Here's what the platform offers: ✅ Show off your innovations, expertise, and services to connect globally and gain valuable insights. ✅ Gain exposure worldwide and network with experts, investors, and distributors. ✅ Showcase your innovations on a global scale. ✅ Connect directly with your target audience. ✅ Receive crucial medical validation for your innovations. ...and much more! Let's be a part of this lively community ➡ https://lnkd.in/epuFDMGX By the way, I highly recommend Kay, an experienced expert in digital health and the pharmaceutical industry, who as Head of Operations Europe at VentureBlick offers support for startups. Revolve Healthcare #healthcareinnovation #VentureBlick #community #networking 

Working closely with the start up ecosystem over the last couple years and us at LSX having an extensive VC network this is a discussion I feel I've had close to daily Very excited to hear what insights these experts will share on the topic. #medtech #healthtech #digihealth #investment #vc

We're thrilled to announce that our CEO, Mika Newton, will be a speaker at the upcoming Bio-IT World Investor Conference. Mika will participate in a panel discussion titled "Empowering Innovation: Build vs. Buy in Data Science and Engineering." 🔍 𝗣𝗮𝗻𝗲𝗹 𝗗𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: This engaging session will dive deep into biotech investment strategies, spotlighting the role of data science in the success of startups and the strategic decision-making in larger pharmaceutical companies. It's an opportunity to explore the dynamics between developing in-house expertise versus leveraging external partnerships, the impact of outsourcing, and how technology assets are valued within the biotech/pharma landscape. A conversation for investors focused on fostering growth in this sector. 📅 𝗠𝗮𝗿𝗸 𝗬𝗼𝘂𝗿 𝗖𝗮𝗹𝗲𝗻𝗱𝗮𝗿𝘀! Date: April 17, 2024 Time: 12:00 PM EST Omni Boston Hotel at the Seaport Boston, MA 🎙️ 𝗙𝗲𝗮𝘁𝘂𝗿𝗶𝗻𝗴 𝗘𝘀𝘁𝗲𝗲𝗺𝗲𝗱 𝗣𝗮𝗻𝗲𝗹𝗶𝘀𝘁𝘀: Dana Callow, Founder & Managing Partner, Boston Millennia Partners Tom Neyarapally, CEO and Co-Founder, Archetype Therapeutics, Inc. Miruna Sasu, President and CEO, COTA, Inc. Christina Vorvis, PhD, Director, AbbVie Ventures Xiaoying Wu, MD,MS, Vice President, Data Science & Digital Health, Johnson & Johnson Innovative Medicine Mika and the team of experts will provide important insights that promise to enrich our understanding of innovation management in the health sector. For more details on the panel and the event, visit: https://lnkd.in/dRnKKURy If you are attending the Bio-IT World Conference & Expo and want to learn more about the xCures Platform, feel free to contact Bryan Federowicz, who will be at the event. #BioITWorld #InvestorConference #DataScience #Biotech #PharmaInnovation #HealthTech

💻 Explore the latest post on biopharma unicorns set for IPOs in 2024! 🦄 #BiopharmaInnovation #IPO2024 #HealthcareFinance 📈 The biopharma sector is experiencing remarkable growth, with several companies gearing up for potential IPOs in 2024. This trend reflects the industry's commitment to innovation and the development of life-changing treatments. 📉 🔬 Technological advancements play a crucial role in driving these biopharma unicorns towards success. By harnessing cutting-edge tools and methodologies, these companies are revolutionizing healthcare and paving the way for future breakthroughs. 👩🏽💻 Embracing diversity in tech is essential for fostering creativity and driving inclusive innovation in the biopharma sector. By encouraging diverse perspectives and talents, companies can unlock new opportunities and enhance their competitive edge. 📍 Learn more about the biopharma unicorns poised for IPOs in 2024 and how NextRound.ai can support founders in navigating the fundraising landscape effectively. 💰💻✅ Visit a href="https://nextround.ai/blog/"NextRound.ai's blog post/a for valuable insights and resources on securing investments for your biopharma venture. #NextRound #BiopharmaFunding #FutureGrowth ☝🏽

The #EUeic and Johnson & Johnson Healthcare Investor Day, powered by EuroQuity - Bpifrance, brought together over 100 attendees, including investors, corporates, and business partners, to explore innovative healthcare solutions. It showcased top EIC Fund Healthcare companies from various verticals such as biotech, eHealth, medtech, and pharmaceuticals. 🚀 This Investor Day attracted over 30 startup representatives, over 40 investors, corporate and business partners, including prominent VC funds providing an exceptional platform for partnerships. 💡 The EIC Investor Readiness and Outreach Programme enhances the Business Acceleration Services (BAS) by promoting co-investment and facilitating connections through matchmaking and dedicated activities. Read the full article for further details and main takeaways. 👉 https://lnkd.in/eMBmWT2w #Healthcare #EuroQuity

Great time today at the MedTech Marketing at Scale #HealthTech #Executive #Panel: "How to Create Success Against All Odds". Avital Adler, PhD, aMoon Fund Keren Leshem, OCON Therapeutics and Daria Lemann-Blumenthal BELKIN Vision gave a star performance, walking us through the market outline for 2024 -2025 and sharing invaluable tips on the investment process from #fundraising to #IPO and #exit. The panelists shared their personal experiences of leading a company in times of challenge, discussed common founders' mistakes, provided tips on how to avoid them, and suggested what companies can do to increase their success chances in the current period. We had a record interest with 175 webinar registrants and so many who joined us online and asked thought-provoking questions. Thank you to our amazing panelists and a huge shout-out to everyone who joined us! It was nothing less than amazing. It was an honor to organize and moderate such a remarkable panel! Comment below if you would like to get the recording. #knowledgesharing #learnfromtheexperts #biotech #healthtech #medtech #growth #markettrends

💡 New Investor Call: Building the next big thing in health tech? Innovestor Life Science, a 90m€ Finland-based fund, is actively seeking new investment opportunities in the Nordics and Baltics! If you're developing science-based or evidence-backed digital health and therapeutics products, this Investor Call could be the perfect fit for you. Details: - Investment Stage: Pre-Seed to Series A - Investment Range: 500k€-3m€ - Focus: All therapeutic areas - Region: Sweden, Finland, Norway, Denmark, Iceland, Estonia, Latvia, Lithuania To learn more and apply on R2GConnect: https://lnkd.in/dAjbQ2Kc #Investors: Visit R2GConnect.com to set up your own 'Investor Call' for #free. For a demo, contact Sorin STIRCU, Partnerships Manager: https://bit.ly/3TGL2kF #StartupFunding #VentureCapital #HealthTech #EarlyStageInvesting #InvestmentOpportunities

#Medtech 𝐕𝐂 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 𝐢𝐧 𝐐1 2024: 𝐅𝐨𝐜𝐮𝐬 𝐨𝐧 𝐐𝐮𝐚𝐥𝐢𝐭𝐲 𝐎𝐯𝐞𝐫 𝐐𝐮𝐚𝐧𝐭𝐢𝐭𝐲: Total deal value hit $3.3 billion, the highest since Q4 2022, despite historically low deal counts. 𝐌𝐚𝐣𝐨𝐫 𝐃𝐞𝐚𝐥𝐬: Freenome led with a $254M round, supported by Roche Venture Fund and Bain Capital Life Sciences. Notable smaller deals included Impulse Dynamics, Mainstay Medical, Alamar Biosciences, and Medical Microinstruments. 𝐈𝐧𝐯𝐞𝐬𝐭𝐨𝐫 𝐀𝐜𝐭𝐢𝐯𝐢𝐭𝐲: Gilde Healthcare and Arboretum Ventures led with three deals each, while Khosla Ventures was among several investors with two investments. 𝐂𝐚𝐭𝐞𝐠𝐨𝐫𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: #Cardiovascular: Over $1.5 billion invested, with Impulse Dynamics' $136M Series E standing out. #Cancer Diagnostics: $395.3 million #Neurostimulation: $242.8 million #PersonalizedCare & #RemoteMonitoring: $226.5 million 𝐕𝐂 𝐄𝐱𝐢𝐭𝐬: Few exits noted, with exceptions like Attune Medical's $160M acquisition by Haemonetics. 𝐈𝐏𝐎 𝐀𝐜𝐭𝐢𝐯𝐢𝐭𝐲: Sparse, with Autonomix raising $11.1 million in its public listing. 𝐏𝐄 𝐀𝐜𝐭𝐢𝐯𝐢𝐭𝐲: Declined with five PE growth deals and 14 buyouts. Interest noted in Healthium Medtech and Baxter’s Vantive kidney care unit. 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐮𝐭𝐥𝐨𝐨𝐤: Despite a strong start, cautious optimism prevails due to lower deal values compared to 2021 highs and uncertain interest rate expectations. Read more at the link below PitchBook #Medtech #VCFunding #InvestmentTrends #HealthcareInnovation #MedicalDevices

It's been just a week since we closed our fiscal year, and I wanted to share some reflections on this year's journey. The market conditions were tough, but we remained steady, and little by little more biotech investments started coming in. We stayed optimistic. This year, we grew our team significantly, and expanded our collaborations. We are fostering stronger bonds across sites and countries, truly becoming one cohesive unit. On the last day of the fiscal year, we achieved some long-awaited lab results that we've been working towards since January. What a way to wrap up the year! While I can't reveal the details just yet, I can promise that it's going to be exciting! Here's to another year of growth and innovation. Cheers to the team and all our partners and collaborators for making this possible! Innovation is not just a goal; it’s a journey. What matters most is the people you share it with. I am very fortunate to spend it with you guys! #TeamGrowth #Innovation #GlobalCollaboration #ExcitingTimesAhead